Home Online Features New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
Press Releases
Novo Nordisk Inc.  
November 3, 2024

New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight

Results from Novo Nordisk, presented at ObesityWeek®, showed treatment with semaglutide injection 2.4 mg resulted in significant reductions in hospital admissions as well as overall time spent in the hospital1Cardiovascular

logo salamanca press

Salamanca Press

email salamanca press
Local & Social